Search clinical trials for: MK-2206

Total 1934 results

Oncoimmune, Inc., a subsidiary of Merck & Co.,...
National Cancer Institute (NCI); University of Michigan Rogel Cancer Center; Ohio... and other collaborators

Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Leukemia | Hematopoietic Stem Cell Transplantation | Graft Versus Host Disease

United States
Ashraf Badros
Merck Sharp & Dohme LLC

Terminated

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
University of Missouri-Columbia
Merck Sharp & Dohme LLC

Enrolling by invitation

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Spine Surgery | Urinary Retention Postoperative | Reversal of Neuromuscular Blockade

United States
University of Washington
Ortho-McNeil Pharmaceutical

Unknown

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Contraception

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Melanoma | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

United States
University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Metastatic Pancreatic Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
OncoImmune, Inc.

Terminated

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)

Acute Graft Versus Host Disease | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Hematopoietic Stem Cell Transplantation

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC

Completed

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Urinary Tract Infections | Pyelonephritis
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) (RUBY)

Insomnia
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Anesthesia
St Stephens Aids Trust

Completed

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

HIV Infections

United Kingdom
National Cancer Institute (NCI)

Recruiting

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

HIV Infection | Advanced Malignant Solid Neoplasm | Kaposi Sarcoma | Lung Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Anal Carcinoma | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States, Australia
National Cancer Institute (NCI)

Suspended

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Locally Advanced Leiomyosarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Locally Advanced Liposarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Locally Advanced Extraskeletal Myxoid Chondrosarcoma | Locally Advanced Unresectable Soft Tissue Sarcoma

United States, Canada
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Children's Oncology Group

Recruiting

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
University of Washington
National Cancer Institute (NCI); United States Department of Defense

Recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Glioblastoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Activating Mutation

United States
Organon and Co

Withdrawn

Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)

Asthma
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Prostate Cancer | Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.

Withdrawn

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Recurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated T-Cell Lymphoma | Recurrent Follicular T-Cell Lymphoma | Recurrent Hepatosplenic T-Cell Lymphoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma
Institut fuer Frauengesundheit
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC (NIB)

Malignant Neoplasm of Breast

Germany
Merck Sharp & Dohme LLC

Completed

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Arthroplasty, Replacement, Knee | Neuromuscular Blockade | Arthroplasty, Replacement, Hip | Blood Coagulation | Antithrombotic Agents
Loyola University
Merck Sharp & Dohme LLC

Completed

Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

Nausea | Vomiting
Institut Bergonié

Completed

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. (ESCALE)

Non-Hodgkin's Lymphoma | Solid Tumors

France
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Anal Canal Squamous Cell Carcinoma | Metastatic Anal Canal Carcinoma | Stage IV Anal Canal Cancer AJCC v6 and v7

United States, Canada
National Cancer Institute (NCI)

Terminated

Vaccine Treatment of Kidney Cancer

Kidney Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Malaria

Australia
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

China
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (DoceRamPem)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Non-Small Lung Cell Cancer | Recurrent Non-Small Lung Cell Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Neuromuscular Blockade

United States, Australia, Belgium, Brazil, Denmark, Finland, France, Guatemala, Hungary, Malaysia, Mexico, Netherlands, Peru, Russian Federation

Search clinical trials for: MK-2206

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations